HIGHLIGHTS
- who: Charlotte Genestet and collaborators from the Hospitalier Nord, Service pharmaceutique, France have published the article: Rifampicin exposure reveals within-host Mycobacterium tuberculosis diversity in patients with delayed culture conversion, in the Journal: (JOURNAL) of June/24,/2021
- what: The authors focused on TB patients with delayed response to treatment and the authors performed genetic characterization of Mtb isolates to search for sub-populations that may tolerate anti-TB drugs. The aim of this study was to address the issue of within-host Mtb micro-diversity and its possible link with anti-TB treatment response . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.